Novozyme plus R-CHOP Regimen for first-line treatment of mantle cell lymphoma
EUROHEALTH, February 5 - the State Drug Administration (nmpa) has approved the first-line clinical trial of the company's independently developed Bruton tyrosine kinase (Btk) inhibitor, orbotinib, combined with R-CHOP, in the treatment of mantle cell lymphoma (MCL), a biomedical company, announced today.
Obutinib is a class 1 innovative drug independently developed by ncjh. It is a new Btk inhibitor for the treatment of lymphoma and autoimmune diseases. On December 25, 2020, obutinib was approved by nmpa for the treatment of relapsed / refractory chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma (SLL) patients and relapsed / refractory MCL patients. On December 31, 2020, obutinib was awarded orphan drug designation by the US Food and Drug Administration for the treatment of mantle cell lymphoma (MCL).
This text is a result of machine translation.
Briefing Jul 30, 2021 11:17 AM
· Healthcare
Robin Li led the creation of biocomputing platform, and the 100 billion dollar A round of financing.
Briefing Jul 30, 2021 09:41 AM
· Healthcare
Baiji China: positive data from zebutinib heavy phase 3 study
In depth
Healthcare
Bid for Molecular Tech in China's Early-Stage Cancer Detection Market
China, with a population of 1.4 billion, has one of the largest gene pools in the world. How does its DNA tech-based cancer detection industry look? Listed on Nasdaq in 2020, Genetron Holdings Limited (Genetron Health) is taking a leading role.
Sep 09, 2020 03:08 PM
Briefing Jul 30, 2021 09:12 AM
· Healthcare
Xingyi'ang biology obtained US $40 million Angel round financing and is committed to developing NK new technology platform and products
Briefing Jul 28, 2021 10:22 PM
· Healthcare
Lupeng pharmaceutical obtained USD 35 million pre-B round of financing and Temasek led the investment
Research
Consumer Staples, Healthcare, TechnologyWIA2020 | Rising Tech Stars 2020: Global & China's 100
Dec 09, 2020 09:57 AM
Dec 09, 2020 09:39 AM
Research
Healthcare, Industrials, FinancialsTech for Global, Globalization Footprints of the Established and the New
May 29, 2020 08:30 PM
Research
Healthcare, Industrials, FinancialsLow-Carbon Industry Expansion - Key Studies From Chinese Companies
May 28, 2020 12:40 PM
Briefing Jul 28, 2021 09:22 AM
· Healthcare
Zanrong pharmaceutical obtained a round B financing of US $40 million, led by OrbiMed (orbo capital)
Briefing Jul 15, 2021 02:22 PM
· Healthcare
Sequoia China leads the investment, Xihu biomedicine gets another billion yuan financing
Briefing Jul 14, 2021 09:25 AM
· Healthcare
Xinwen biological completed tens of millions of Yuan Angel round financing to accelerate the development and industrialization of innovative transdermal drugs
Briefing Jul 08, 2021 09:26 AM
· Healthcare
Xingkang protobio obtained tens of millions of US dollars in a + round financing, and continued to promote and expand the innovative drug pipeline
Healthcare
Sinopharm COVID Vaccine Receives WHO Emergency Use Certification
The Sinopharm Group’s COVID Vaccine is the sixth vaccine to receive safety, efficacy and quality verification from the World Health Organization (WHO). It is the first vaccine from a non-Western country to receive WHO certification.
May 11, 2021 03:35 AM
Healthcare
Yunnan Baiyao's Revenue Rises 33%; Net Profit Falls 40% in 1Q 2021
On April 27, Yunnan Baiyao released a report for the first quarter of 2021 showing that the company's total operating revenue for the first quarter was 10.33 billion yuan, up 33.4% year-on-year; its operating profit was 880 million yuan, down 41.8% year-on-year; its net profit attributable to shareholders of the listed company was 760 million yuan.
Apr 30, 2021 02:07 AM
Briefing Jul 07, 2021 02:58 PM
· Healthcare
US $8.5 billion, EQT IX fund and Goldman Sachs reach an acquisition agreement with JINGDING pharmaceutical
Briefing Jul 07, 2021 01:19 PM
· Healthcare
A new round of dynamic adjustment of the national health insurance catalogue has been launched, and new drugs of aberway have taken the initiative to reduce prices to "pave the way" for health insurance negotiations
Briefing Jul 07, 2021 10:50 AM
· Healthcare
Zhinuobio, an innovative drug R & D enterprise of nuclear medicine, obtained 100 million yuan of round C financing
Healthcare
Revenue and Net Profit of Wuxi Apptec Both Increased in 2020
Wuxi apptec said that the main reasons for the company's performance growth were the high growth of laboratories in China and the year-on-year growth of CDMO plate. China laboratory service is the core business of Wuxi apptec, accounting for more than 50% of its revenue. Its main business is small molecule drug discovery, drug analysis and testing.
Apr 01, 2021 04:39 PM
Briefing Jul 02, 2021 02:10 PM
· Healthcare
Li Jidian: the production capacity of next year has been fully reserved, and it can be listed before the end of the year
Briefing Jun 02, 2021 10:03 AM
· Healthcare
Baiji Shenzhou: efficacy and safety advantages confirmed by global phase 3 head-on study of zebutinib
Briefing May 27, 2021 02:02 AM
· Healthcare
Alibaba Health Information publishes rather poor annual figures
Briefing May 13, 2021 06:43 PM
· Healthcare
HealthTech Miaoshou Doctor (Tencent Investment) ahead of IPO
See more
Read next
Automotive · Analysis
NIO Sprints Back into Growth Mode – and There Is No Regulatory Risk Thus Far
Yesterday 10:55 AM
In depth
Consumer Staples
Farmmi: A Chinese Agriculture Brand Set to Capitalize on New Wellness Trends
Aug 02, 2021 10:47 AM
Automotive · Analysis
2022 Might Be a Winning Year for Xpeng – and the Stock Is Finally Fairly Priced Now
Jul 29, 2021 04:01 PM
EqualOcean is an information service provider and investment research company that aims to become a global platform for industrial innovation. Founded in February 2014 and headquartered in Beijing, with a client network covering over 50 countries, the firm provides comprehensive professional services, including industry research, investment analysis, innovation consulting, data products, corporate branding and international strategy.